- This event has passed.
Cancer Medicine and Hematology – Harvard Medical School
September 25, 2016 - September 30, 2016$1,500
Management of patients with cancer and with benign hematologic disorders has changed considerably in recent years and continues to evolve rapidly. Oncologists, hematologists, internists, and other members of the cancer care team must stay abreast of recent advances in numerous practice areas, including:
- Appropriate selection and interpretation of genetic and molecular testing
- Uses of new diagnostic paradigms and classification schemes
- Treatment selection from a broad array of systemic therapies, including targeted therapies, immunologic approaches, and chemotherapeutic agents
- Effective integration of systemic therapies into management schemes that include additional treatment modalities, such as surgery and radiation, when appropriate
- Evidence-based management of patients’ supportive and palliative care needs
- Comprehensive strategies for meeting the needs of a burgeoning population of cancer survivors
Cancer Medicine and Hematology is an intensive, 6-day educational activity that is specifically designed to provide clinicians with a comprehensive review of up-to-date practice standards for a broad range of solid tumors, hematologic malignancies, and benign hematologic disorders. Taught by expert Harvard Medical School faculty as well as invited experts, the course features a discussion of the most recent clinical trial data, recently updated guidelines, and current expert opinion with impacts on management decisions for patients with these disorders. The highly interactive course is presented through a mixture of engaging lectures followed by question and answer sessions, case-based presentations and panel reviews of participants’ challenging cases, and disease-specific panel discussions. A two-volume syllabus and a thumb drive with copies of each speaker’s outline and slides ensures that clinicians can return to this material again and again as needed to inform and improve their practices, leading to improved patient outcomes.
Upon completion of this course, participants will be able to:
- Develop treatment strategies for benign hematologic disorders and hematologic malignancies, including appropriate selection of systemic therapies where applicable and effective monitoring and management of patients with long-term conditions
- Select evidence-based treatment regimens for different types and stages of breast cancer, including HER2+, ER+, and triple negative, in pre – and post-menopausal women
- Use recent clinical trial results and current guidelines to select appropriate molecular testing for lung, head and neck cancers and apply test results to the selection of optimal therapeutic approaches
- Assess recent clinical evidence on treatment approaches for gastrointestinal and neuroendocrine cancers and apply in specific patient scenarios
- Recognize recent advances and apply current guidelines to the management of prostate, testicular, renal, and bladder cancers
- Apply recent clinical evidence to the selection of treatment approaches for ovarian, cervical, endometrial, and trophoblastic cancers
- Develop updated management strategies for less commonly encountered malignancies including brain tumors, thyroid cancer, metastatic melanoma, sarcoma, and mesothelioma
- Assess patients’ needs for supportive and survivorship care and develop evidence-based strategies for meeting these needs
- Recognize supportive care needs of patients across the spectrum of cancer types and stages and use evidence-based best practices to manage symptoms such as pain, depression, and chemotherapy-induced nausea and vomiting
- Develop survivorship care plans for cancer patients that include appropriate types and intervals for testing, best practices for symptom management, and appropriate counseling on diet and lifestyle changes
Who Should Attend
The course is directed to specialty physicians.